Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$15.55
-2.7%
$17.66
$11.13
$98.00
$146.03M2.6698,145 shs127,731 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$12.13
+2.3%
$14.15
$5.22
$27.38
$152.69M0.41139,547 shs131,527 shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$3.01
-1.0%
$3.10
$2.23
$5.20
$149.39M1.29442,619 shs310,742 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$0.97
-0.3%
$0.95
$0.73
$3.07
$37.62M1.65174,712 shs22,370 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Korro Bio, Inc. stock logo
KRRO
Korro Bio
+2.70%-9.56%+23.88%-47.33%-68.67%
LifeVantage Co. stock logo
LFVN
LifeVantage
-3.34%+0.68%-16.12%-39.74%+77.01%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
+4.47%-0.98%+7.80%+10.14%-36.80%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
+2.25%-0.08%+11.30%-17.94%-50.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Korro Bio, Inc. stock logo
KRRO
Korro Bio
2.0609 of 5 stars
4.60.00.00.02.10.00.6
LifeVantage Co. stock logo
LFVN
LifeVantage
3.994 of 5 stars
3.51.01.72.72.21.71.3
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.7964 of 5 stars
3.51.00.00.02.73.33.1
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
1.1095 of 5 stars
0.04.00.00.03.30.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Korro Bio, Inc. stock logo
KRRO
Korro Bio
3.25
Buy$104.63572.83% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50151.44% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.00132.56% Upside
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SCYX, PBYI, KRRO, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$155.00 ➝ $90.00
5/8/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$115.00 ➝ $100.00
4/29/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$74.00
4/16/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
3/20/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$115.00 ➝ $115.00
3/19/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$105.00 ➝ $95.00
2/28/2025
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$4.82M30.29N/AN/A$21.19 per share0.73
LifeVantage Co. stock logo
LFVN
LifeVantage
$222.35M0.69$0.64 per share19.03$2.38 per share5.10
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$230.47M0.65$0.72 per share4.19$1.12 per share2.69
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.75M10.04$1.66 per share0.58$1.96 per share0.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$81.17M-$9.44N/AN/AN/AN/A-50.25%-38.48%5/13/2025 (Estimated)
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.6921.66N/A3.46%34.29%15.04%N/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$21.59M$0.776.277.92N/A9.56%41.60%10.71%N/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$67.04M-$0.44N/A19.30N/A-425.41%-66.21%-38.84%5/14/2025 (Estimated)

Latest SCYX, PBYI, KRRO, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23N/AN/AN/A$0.14 millionN/A
5/7/2025Q1 2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 million
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/18/2025Q4 2024
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$2.33-$2.26+$0.07-$2.26N/A$2.27 million
3/12/2025Q4 2024
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.22-$0.09+$0.13-$0.09N/A$0.98 million
2/27/2025Q4 2024
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.10$0.39+$0.29$0.39$52.50 million$59.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.181.48%N/A26.09%2 Years
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A

Latest SCYX, PBYI, KRRO, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/A
11.23
11.23
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.46
1.42
1.40
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
3.13
3.13

Institutional Ownership

CompanyInstitutional Ownership
Korro Bio, Inc. stock logo
KRRO
Korro Bio
13.18%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Korro Bio, Inc. stock logo
KRRO
Korro Bio
5.40%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
23.70%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
2.85%
CompanyEmployeesShares OutstandingFree FloatOptionable
Korro Bio, Inc. stock logo
KRRO
Korro Bio
709.39 million8.86 millionNo Data
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.59 million9.96 millionOptionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20049.63 million37.45 millionOptionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
6038.98 million36.87 millionOptionable

Recent News About These Companies

SCYNEXIS (SCYX) Projected to Post Earnings on Wednesday
Scynexis to present preclinical data on SCY-247 at ESCMID Meeting
SCYNEXIS Full Year 2024 Earnings: Misses Expectations
Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Korro Bio stock logo

Korro Bio NASDAQ:KRRO

$15.55 -0.43 (-2.69%)
As of 04:00 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$12.13 +0.27 (+2.28%)
As of 04:00 PM Eastern

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$3.01 -0.03 (-0.99%)
As of 04:00 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$0.97 0.00 (-0.32%)
As of 04:00 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.